Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Sutimlimab (DHC43601)

Host species:Humanized
Isotype:IgG4-kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHC43601

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG4-kappa

Clonality

Monoclonal

Target

C1 esterase, Complement C1s subcomponent, C1S, Complement component 1 subcomponent s

Concentration

3.07 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P09871

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

BIVV009, IPN-009, TNT009, CAS: 2049079-64-1

Clone ID

Sutimlimab

Data Image
  • SDS-PAGE
    SDS PAGE for Sutimlimab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Autoimmune hemolytic anemia, PMID: 30504336

Antibodies to watch in 2020, PMID: 31847708

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial, PMID: 30559259

New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1, PMID: 33261023

Novel insights into the treatment of complement-mediated hemolytic anemias, PMID: 31523413

Sutimlimab in Cold Agglutinin Disease, PMID: 33826820

C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro, PMID: 30635392

A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway, PMID: 29737533

Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program, PMID: 32176765

2019 ASH Annual Meeting, PMID: 31859224

Cold agglutinin disease: current challenges and future prospects, PMID: 31114413

How I treat cold agglutinin disease, PMID: 33512410

Specific Inhibition of the Classical Complement Pathway Prevents C3 Deposition along the Dermal-Epidermal Junction in Bullous Pemphigoid, PMID: 31229501

Serum complement levels in immune thrombocytopenia: Characterization and relation to clinical features, PMID: 32685889

Datasheet

Document Download

Research Grade Sutimlimab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Sutimlimab [DHC43601]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only